Exemestane

依西美坦

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameExemestane
Drug Alias Name备依西美坦ExemestanoEXEExemestanumNikidess +[8] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionAromatase inhibitors
TargetsAromatase
Therapy Area/IndicationsMetastatic breast cancerHyperplasiaEndometrial Hyperplasia +[11] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date1998/12/16
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteMasonic Cancer Center, University Of MinnesotaPfizer Inc +[5] 
Inactive CompaniesGeorgetown UniversityRobert H. Lurie Comprehensive Cancer Center Of Northwestern UniversityActavis Inc +[8] 
Active IndicationsHyperplasiaEndometrial HyperplasiaAtaxia Telangiectasia +[9] 
Inactive IndicationsMetastatic breast cancerOvarian Neoplasms

Other Information

ATC CodeL02BG06
Related LinksWikipediaDrugBankKEGG